BarbaraJaneKlenckeMD

PubMed

• 52 citations
  Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conju...
  Manish Gupta, Patricia LoRusso, Bei Wang, Joo-Hee Yi, Howard A. Burris, Muralidhar Beeram, Shanu Modi, Yu-Waye Chu, Samuel Agresta, Barbara Klencke, Amita Joshi, Sandh...> ;Journal of Clinical Pharmacology. 2012 May 1
• 509 citations
  Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior ...
  Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, Rachel A. Borson, Steven A. Limentani, Elizabeth Tan-Chiu, Ian E. Krop, Richard Alan Michaelso...> ;Journal of Clinical Oncology. 2011 Feb 1
• 88 citations
  Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
  W. K. Alfred Yung, James J. Vredenburgh, Timothy F. Cloughesy, Phioanh L. Nghiemphu, Barbara Klencke, Mark R. Gilbert, David A. Reardon, Michael D. Prados> ;Neuro-Oncology. 2010 Oct 1
• A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.
  Vogel CL, Burris HA, Limentani S, Borson R, O'Shaughnessy J, Vukelja S, Agresta S, Klencke B, Birkner M, Rugo H> ;J. Clin. Oncol.. 2009-05-20
• Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-D...
  Krop IE, Burris HA, Rugo H, O'Shaughnessy J, Vogel CL, Amler L, Strauss A, Wong EK, Klencke B, Pippen J> ;J. Clin. Oncol.. 2009-05-20
• Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer...
  Klencke BJ, Bhattacharya S, Samant MK, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE, Miller KD> ;J. Clin. Oncol.. 2008-05-20
• Clinical pharmacokinetics of erlotinib (E) in glioblastoma multiforme (GBM) patients and its implication for dosing.
  Lu J, Eppler S, Ling J, Prados M, Klencke B, Lum B> ;J. Clin. Oncol.. 2006-06-20
• Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome.
  Cloughesy T, Yung A, Vrendenberg J, Aldape K, Eberhard D, Prados M, Vandenberg S, Klencke B, Mischel P> ;J. Clin. Oncol.. 2005-06-01
• Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial.
  Yung A, Vredenburgh J, Cloughesy T, Klencke BJ, Mischel PS, Bigner DD, Aldape K, Vanderburg S, Prados M> ;J. Clin. Oncol.. 2004-07-15
• 98 citations
  Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors.
  Anthony T.C. Chan, Qian Tao, Keith D. Robertson, Ian W. Flinn, Risa B. Mann, Barbara Klencke, Wing Hong Kwan, Thomas W.T. Leung, Philip J. Johnson, Richard F. Ambinder> ;Journal of Clinical Oncology. 2004 Apr 15
• 100 citations
  High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
  Brian Rose, Katherine K. Matthay, David Price, John P. Huberty, Barbara Klencke, Jeffrey A. Norton, Paul A. Fitzgerald> ;Cancer. 2003 Jul 15
• 40 citations
  Anal cancer: an HIV-associated cancer.
  Barbara Klencke, Joel M. Palefsky> ;Hematology/oncology Clinics of North America. 2003 Jun 1
• 50 citations
  Altered clinical course of malignant melanoma in HIV-positive patients.
  Lori K. E. Rodrigues, Barbara J. Klencke, Kirsten Vin-Christian, Timothy G. Berger, Richard I. Crawford, James R. Miller, Carlos M. M. Ferreira, Mehdi Nosrati, Mohamme...> ;Archives of Dermatology. 2002 Jun 1
• 175 citations
  Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.
  Barbara Klencke, Mark Matijevic, Robert G. Urban, Janet L Lathey, Mary Lynne Hedley, Michael J. Berry, Joe Thatcher, Vivian Weinberg, Jennifer Wilson, Teresa M. Darrag...> ;Clinical Cancer Research. 2002 May 1
• 83 citations
  The restricted cellular host range of human herpesvirus 8.
  David J. Blackbourn, Evelyne T. Lennette, Barbara Klencke, Ashlee V. Moses, Bala Chandran, Mark Weinstein, Richard G. Glogau, Marlys H. Witte, D. Way, Tim Kutzkey, Bri...> ;AIDS. 2000 Jun 16
• 131 citations
  THE SIGNIFICANCE OF PRETREATMENT CD4 COUNT ON THE OUTCOME AND TREATMENT TOLERANCE OF HIV-POSITIVE PATIENTS WITH ANAL CANCER
  Rex Hoffman, Mark L. Welton, Barbara Klencke, Vivian Weinberg, Richard Krieg> ;International Journal of Radiation Oncology, Biology, Physics. 1999 Apr 1
• 4 citations
  Advances and future challenges in non-Hodgkin's lymphoma.
  Barbara Klencke, Lawrence D. Kaplan> ;Current Opinion in Oncology. 1998 Sep 1
• Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile.
  Dorsey, B. V., Benjamin, L. E., Rauscher, F., Klencke, B., Venook, A. P., Warren, R. S., Weidner, N.> ;Mod Pathol. 1996 Jun
• 13 citations
  Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma
  Al B. Benson, Edith P. Mitchell, N. Abramson, B. Klencke, Paul S. Ritch, J. P. Burnham, C. McGuirt, T. Bonny, J. Levin, John A. Hohneker> ;Annals of Oncology. 2002 Apr 1
• Join now to see all